The term NSD and its accompanying integrated staging system have only recently been proposed in a single article,4 and have not been sufficiently considered, vetted, and supported by large segments of the research community dealing with alpha synuclein–related diseases (the community at large currently rather uses the term “Lewy body disorder” or “Lewy body disease” as the umbrella term for PD and DLB5, 6 and we have also argued that the diagnosis of PD should not be restricted to those with Lewy pathology).3 The gene discussed is SNCA; the disease is Lewy body dementia.